Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial

Journal:
Nature Medicine
Published:
Affiliations:
25
Authors:
25
Institutions Authors Share
Daiichi Sankyo US, United States of America (USA)
3.000000
0.12
August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Spain
2.000000
0.08
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)
1.000000
0.04
Institut de Recherche en Cancérologie de Montpellier (IRCM), France
1.000000
0.04
Nagoya City University, Japan
1.000000
0.04
Samsung Medical Center (SMC), South Korea
1.000000
0.04
The First Hospital of Jilin University, China
1.000000
0.04
Showa Medical University, Japan
1.000000
0.04
University of Hawaiʻi Cancer Center, United States of America (USA)
1.000000
0.04
University Hospital of Lausanne (CHUV), UNIL, Switzerland
1.000000
0.04
Euromedica General Clinic, Greece
1.000000
0.04
UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC), United States of America (USA)
1.000000
0.04
Kanagawa Cancer Center, Japan
1.000000
0.04
University Hospital of Munich (KUM), LMU, Germany
1.000000
0.04
Seoul National University Hospital (SNUH), South Korea
1.000000
0.04
IRCCS Istituto Nazionale Tumori IRCCS-Fondazione G. Pascale, Italy
1.000000
0.04
Curie Institute, France
1.000000
0.04
Zhejiang Cancer Hospital (ZJCH), China
1.000000
0.04
Institute Jules Bordet, ULB, Belgium
1.000000
0.04
Kyushu Cancer Center, Japan
1.000000
0.04
Daiichi Sankyo France SAS, France
1.000000
0.04
The University of Edinburgh, United Kingdom (UK)
1.000000
0.04